Fosamprenavir
Links shared publicly online about this topic
Pharmacokinetics of Darunavir and Fosamprenavir in Pregnancy - The Body
thebody.com — “Physiological changes in pregnancy can affect drug disposition. Plasma concentrations of several PIs -- including lopinavir, atazanavir and saquinavir -- ...” View full resource at thebody.com
Most Recently Shared on September 5, 2011 at 1:00 pm By:
IAS 2011: Pharmacokinetics of Darunavir and Fosamprenavir in Pregnancy http://t.co/Ie29qhi #ias2011 #child #hiv #aids
FDA: Link between fosamprenavir and MI, dyslipidemia
theheart.org — “Fosamprenavir calcium is associated with an increased risk of MI and dyslipidemia in HIV-infected adults, according to the FDA.” View full resource at theheart.org
Most Recently Shared on December 8, 2009 at 6:11 pm By:
FDA warning: Increased MI, dyslipidemia with fosamprenavir http://bit.ly/5UVUcD #heartwire
FDA Alert: Lexiva (fosamprenavir calcium) - Dear Healthcare Professional Letter
drugs.com — “FDA Alert: Lexiva (fosamprenavir calcium) - Dear Healthcare Professional Letter” View full resource at drugs.com
Most Recently Shared on December 4, 2009 at 7:44 pm By:
FDA Alert - GlaxoSmithKline and FDA Inform Healthcare Professionals of New Warnings for Lexiva (fosamprenavir) - http://bit.ly/8j4QC2
Pediatrics Medical News about Human Immunodeficiency Virus
mdlinx.com — “Long-Term Efficacy and Safety of Fosamprenavir in Human Immunodeficiency Virus-Infected Pediatric Patients” View full resource at mdlinx.com
Most Recently Shared on June 21, 2010 at 9:57 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Long-Term Efficacy and Safety of Fosamprenavir in Human Immunodeficiency Virus-Infected Pediatric Patients: T... http://bit.ly/cYDJWO #peds
Infectious Dis. Medical News about Human Immunodeficiency Virus
mdlinx.com — “Long-Term Efficacy and Safety of Fosamprenavir in Human Immunodeficiency Virus-Infected Pediatric Patients” View full resource at mdlinx.com
Most Recently Shared on June 21, 2010 at 5:17 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Long-Term Efficacy and Safety of Fosamprenavir in Human Immunodeficiency Virus-Infected Pediatric Patients: The... http://bit.ly/9PW5fm #ID
Allergy/Imm Medical News about HIV-1
mdlinx.com — “Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-Naive HIV-1-Infected Adult Subjects” View full resource at mdlinx.com
Most Recently Shared on February 12, 2010 at 12:11 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Allergy/Immunology Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/... http://bit.ly/aaOMSs
Infectious Dis. Medical News about HIV-1
mdlinx.com — “Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once Daily in Antiretroviral-Naive HIV-1-Infected Adult Subjects” View full resource at mdlinx.com
Most Recently Shared on February 12, 2010 at 10:00 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
I/D Study of Once-Daily Versus Twice-Daily Fosamprenavir plus Ritonavir Administered with Abacavir/Lamivudine Once... http://bit.ly/bXvoEi
Infectious Dis. Medical News about HIV
mdlinx.com — “Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Daily with Tenofovir/Emtricitabine in Antiretroviral-Naive HIV-Infected Patients” View full resource at mdlinx.com
Most Recently Shared on May 15, 2010 at 10:44 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Impact of Low Abundance HIV Variants on Response to Ritonavir-Boosted Atazanavir or Fosamprenavir Given Once Da... http://bit.ly/bUll4W #ID
FDA warns of potential cardiovascular risk with Lexiva in HIV-infected patients - MPR
empr.com — “The FDA and GlaxoSmithKline have notified healthcare professionals of a potential association between Lexiva (fosamprenavir calcium) and myocardial infarction and dyslipidemia in HIV-infected adults.” View full resource at empr.com
Most Recently Shared on December 3, 2009 at 10:09 pm By:
MPR News: FDA warns of potential cardiovascular risk with Lexiva in HIV-infected patients: The FDA and GlaxoSmithKl... http://bit.ly/6eyGj4
Symposier - Cardiovascular Problems with Lexiva (February 2010)
symposier.com — “Uploaded and Shared in Youtube by: LawsuitGuru GlaxoSmithKline is notifying healthcare professionals that Lexiva (fosamprenavir calcium), a protease inhibitor, has been associated with an increased risk of myocardial infarction and dyslipidemia in HIV infected adults. The company's letter recommends that patients have their cholesterol and triglycerides tested prior to starting therapy with Lexiva and at periodic intervals during treatment with the drug. The letter also recommends treating ” View full resource at symposier.com
Most Recently Shared on February 4, 2010 at 9:31 pm By:
Symposier Cardiology Cardiology and Health Business
Cardiovascular Problems with Lexiva (fosamprenavir calcium, protease inhibitor) (February 2010) -- >http://ow.ly/13Zgr
Family Medicine Article | HIV
mdlinx.com — “Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study)” View full resource at mdlinx.com
Most Recently Shared on January 21, 2011 at 1:08 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Viral response in stable patients switching to fosamprenavir/ritonavir monotherapy (the FONT Study)... http://bit.ly/idzQ2X #FamPractice
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
The Body
The Complete HIV/AIDS Resource.
-
Shelley Wood
Managing editor for heartwire on theheart.org--the most authoritative, balanced, and insightful cardiovascular disease news online. http://is.gd/nHJ4
-
Drugs.com
Keeping you up to date with the latest medication news, FDA Medwatch alerts and new drug approvals.
Advertisement
